Cargando…

Molecular basis for the antagonistic activity of an anti-CXCR4 antibody

Antagonistic antibodies targeting the G-protein C-X-C chemokine receptor 4 (CXCR4) hold promising therapeutic potential in various diseases. We report for the first time the detailed mechanism of action at a molecular level of a potent anti-CXCR4 antagonistic antibody (MEDI3185). We characterized th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Li, Damschroder, Melissa M., Cook, Kimberly E., Wu, Herren, Dall'Acqua, William F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966504/ https://www.ncbi.nlm.nih.gov/pubmed/26514996 http://dx.doi.org/10.1080/19420862.2015.1113359

Ejemplares similares

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody
por: Peng, Li, et al.
Publicado: (2015)

Molecular basis for the mechanism of action of an anti-TACE antibody
por: Peng, Li, et al.
Publicado: (2016)

Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-interferon antibody fragment and human interferon α-2A
por: Oganesyan, Vaheh, et al.
Publicado: (2008)

Bi-Epitope SPR Surfaces: A Solution to Develop Robust Immunoassays
por: Peng, Li, et al.
Publicado: (2014)

Mechanisms of Neutralization of a Human Anti-α-toxin Antibody
por: Oganesyan, Vaheh, et al.
Publicado: (2014)

Insights into the molecular basis of a bispecific antibody's target selectivity
por: Mazor, Yariv, et al.
Publicado: (2015)

Long-acting antibody ligand mimetics for HER4-selective agonism
por: Shan, Lu, et al.
Publicado: (2020)

Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody
por: Oganesyan, Vaheh, et al.
Publicado: (2018)

Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab
por: Oganesyan, Vaheh, et al.
Publicado: (2015)

Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action
por: Geoghegan, James C., et al.
Publicado: (2016)

Generation and Characterization of an IgG4 Monomeric Fc Platform
por: Shan, Lu, et al.
Publicado: (2016)

The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA
por: Peng, Li, et al.
Publicado: (2012)

Discovery and characterization of potent IL-21 neutralizing antibodies via a novel alternating antigen immunization and humanization strategy
por: Varkey, Reena, et al.
Publicado: (2019)

Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen
por: Wang, Bo, et al.
Publicado: (2019)

In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance
por: Shan, Lu, et al.
Publicado: (2021)

Structural characterization of a human Fc fragment engineered for lack of effector functions
por: Oganesyan, Vaheh, et al.
Publicado: (2008)

Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
por: Mazor, Yariv, et al.
Publicado: (2017)

Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non–small-cell lung carcinoma and rodent tumor models
por: Allen, Kevin L., et al.
Publicado: (2020)

Correction: Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non–small-cell lung carcinoma and rodent tumor models
por: Allen, Kevin L., et al.
Publicado: (2021)

Anti-MrkA Monoclonal Antibodies Reveal Distinct Structural and Antigenic Features of MrkA
por: Wang, Qun, et al.
Publicado: (2017)

Enhancement of Immune Effector Functions by Modulating IgG’s Intrinsic Affinity for Target Antigen
por: Mazor, Yariv, et al.
Publicado: (2016)

Structural insights into the interaction of human IgG1 with FcγRI: no direct role of glycans in binding
por: Oganesyan, Vaheh, et al.
Publicado: (2015)

CXCR4 antagonists for treatment of breast cancer
por: Cortés, Javier, et al.
Publicado: (2018)

Prevention of Fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region
por: Handlogten, Michael W., et al.
Publicado: (2020)

Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström’s Macroglobulinemia
por: Kaiser, Lisa Marie, et al.
Publicado: (2021)

Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5
por: Fang, Xiaocui, et al.
Publicado: (2017)

Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies
por: Peng, Sheng-Bin, et al.
Publicado: (2016)

Synthesis and Anti-HIV Activity of a Novel Series of Isoquinoline-Based CXCR4 Antagonists
por: Shad, Mastaneh Safarnejad, et al.
Publicado: (2021)

CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking
por: Pluchino, Nicola, et al.
Publicado: (2020)

Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587
por: Peng, Sheng-Bin, et al.
Publicado: (2017)

EPI-X4, a novel endogenous antagonist of CXCR4
por: Buske, Christian, et al.
Publicado: (2015)

A Novel Dual Expression Platform for High Throughput Functional Screening of Phage Libraries in Product like Format
por: Xiao, Xiaodong, et al.
Publicado: (2015)

CCR5 and CXCR4 antagonist and agonist binding sites
por: Teintze, Martin, et al.
Publicado: (2006)

Identification of Anti-Malarial Compounds as Novel Antagonists to Chemokine Receptor CXCR4 in Pancreatic Cancer Cells
por: Kim, Joseph, et al.
Publicado: (2012)

Fluorescent CXCR4 chemokine receptor antagonists: metal activated binding
por: Khan, Abid, et al.
Publicado: (2007)

CXCR4 antagonists in hematologic malignancies: more than just mobilizers?
por: Jo, Deog-Yeon
Publicado: (2011)

CXCR4 antagonists suppress small cell lung cancer progression
por: Taromi, Sanaz, et al.
Publicado: (2016)

Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists
por: Morimoto, Mamoru, et al.
Publicado: (2016)

Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates
por: Costa, Maria José, et al.
Publicado: (2019)

Anti-CXCR4 Single-Chain Variable Fragment Antibodies Have Anti-Tumor Activity
por: Liang, Guang-Quan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2q731il843aa5itj8ark1o1vi4